Life Sciences Firm Cure Ventures Announces $350M Fund
Gunderson Dettmer represented client Cure Ventures in the formation of its $350 million inaugural fund. Cure Ventures invests in early-stage life sciences and biotechnology companies with a primary focus on groundbreaking curative technologies.
In the announcement of the fund formation, Cure Ventures’ co-founder and managing partner Richard Lim said, “Biopharma venture capital is an enterprise in risk management that demands rigor, diligence and patience. At Cure, we aren’t just signing a check. We are committed to working closely with founders to collaborate and operationalize capital, making us a true sweat equity partner."
The Gunderson Dettmer deal team was led by Malcolm Nicholls and included Nick Dawson and Hannah Carlson.